Hematologic and cytogenetic response to lenalidomide in de novo acute myeloid leukemia with chromosome 5q deletion

Leukemia Research

Volumn 33, Issue 6, 2009, Pages

  Peñarrubia, Maria J ^a   Silvestre, Luz A ^a   Conde, Joaquina ^a   Cantalapiedra, Alberto ^a   Garcia Frade, Luis J ^a  

^a HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; LENALIDOMIDE;

ACUTE MYELOBLASTIC LEUKEMIA; AGED; ANAMNESIS; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CASE REPORT; CHROMOSOME 5Q; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG MECHANISM; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; HUMAN TISSUE; KARYOTYPE; LABORATORY TEST; LETTER; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 63349101923     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.11.017     Document Type: Letter

References (6)

1. Mrozek K., Heerema N.A., and Bloomfield C.D. Cytogenetics in acute leukemia. Blood Rev 18 (2004) 115-136
2. Estey E.H., Pierce S., and Keating M.J. Identification of a group of AML/MDS patients with a relatively favorable prognosis who have chromosome 5 and/or 7 abnormalities. Haematologica 85 (2000) 246-249
3. List A., Dewald G., Bennett J., Giagounidis A., Raza A., Feldman E., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355 (2006) 1456-1465
4. Lancet J.E., List A.F., and Moscinski L.C. Treatment of deletion 5q acute myeloid leukemia with lenalidomide. Leukemia 21 (2007) 586-588
5. Mesa R.A., Tefferi A., Li C.Y., and Steensma D.P. Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome. Leukemia 20 (2006) 2063-2064
6. Melchert M., Kale V., and List A. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes. Curr Opin Hematol 14 (2007) 123-129